Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.

NCT02355899 | Completed Phase 2

• 1 other identifier: OM 01
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 2

Brief Summary

This study evaluates the potential usefulness of photodynamic therapy with PD P 506 A in patients with distal subungual onychomycosis of the great toenail. Patients will receive four PDT treatments with PD P 506 A in weekly intervals.

Conditions

Onychomycosis

Outcome Measures

Primary Outcomes (1)

• Percentage of nails with Clinically Complete Cure

  The Complete Clinical Clearance of each treated nail will be determined 3, 6 and 12 months after last study treatment. Based on a visual inspection, the nail(s) will either be defined as "completely cleared" or "partially" or "not cleared". To be defined as "completely cleared", a nail must show 100% absence of the 4 following clinical signs of onychomycosis (according to Scher et al., J Am Acad Dermatol. 2007 Jun;56(6):939-44): * Residual changes of the nail plate compatible with dermatophyte infection * White/yellow or orange brown/patches or streaks in or beneath the nail * Lateral onycholysis with debris in an otherwise clear nail plate * Hyperkeratoses on the lateral nail plate/nailfold edge. If the nail shows an improvement but still one of the above signs, it will be rated as "partially cleared". If the nail shows no improvement in comparison to the Screening Visit, it will be rated as "not cleared".

  12 months after last study treatment

Secondary Outcomes (7)

• Percentage of nails with negative laboratory test results for onychomycosis (KOH test, periodic acid-Schiff (PAS) stain and mycology culture).

  12 months after last study treatment

• Percentage of nails with Clinically Complete Cure

  3 and 6 months after last study treatment

• Frequency of adverse events

  During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment

• Severity (grade1-5) of adverse events

  During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment

• Frequency of local reactions.

  During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment

Study Arms (1)

PD P 506 A-PDT

EXPERIMENTAL

One PD P 506 A-patch will be administered to each great toenail for 4 hours. After removal of the study medication the study nail(s) s will be illuminated with red light of defined wavelength (PDT).

Drug: PD P 506 A

Interventions

PD P 506 A DRUG

PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².

Also known as: Alacare®

PD P 506 A-PDT

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male 18 - 75 years of age
• Females up to an age of 75 years provided that they are postmenopausal, i.e. with spontaneous amenorrhea for at least 12 months or not of childbearing potential because of tubal ligation or hysterectomy
• DSO of at least one of the great toe(s) affecting 20% to 60% of the target nail without spikes, confirmed before Visit 1 by at least one of the three methods: the methods of KOH test, periodic acid-Schiff (PAS) stain and mycology culture
• The toenail infection can be due to a dermatophyte, yeast or mixed infections (dermatophyte and non-dermatophyte)
• Toenails have to be cut regularly (indicator for existing growth)
• Signed written informed consent

You may not qualify if:

• Patients with the target toenail involving the matrix (lunula) or having less than 2 mm clear (unaffected) nail plate length beyond the proximal fold
• Presence of dermatophytoma (defined as demarcated and localised thick masses (≥ 3 mm) of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail
• Other conditions than DSO known to cause abnormal nail appearance
• Topical antifungal treatment of the nails within 1 month before PDT
• Systemic use of antifungal treatment within 3 months before PDT
• Patients who are unwilling to provide nail clippings
• Patients who have been previously reported to be allergic against 5-aminolevulinic acid or other ingredients of PD P 506 A
• Diagnosis of porphyria
• Diagnosis of polyneuropathy
• Dementia or psychic condition that might interfere with the ability to understand the study and thus give written informed consent
• Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment

Sponsors & Collaborators

• photonamic GmbH & Co. KG: lead

Study Sites (2)

Klinik für Dermatologie, Klinikum Lippe

Detmold, 32756, Germany

Location

Klinik für Dermatologie und Allergologie KLINIKUM VEST GMBH Knappschaftskrankenhaus Recklinghausen

Recklinghausen, 45657, Germany

Location

MeSH Terms

Conditions

Onychomycosis

Condition Hierarchy (Ancestors)

Tinea; Dermatomycoses; Mycoses; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Nail Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Rolf-Markus Szeimies, Prof. Dr.

  KLINIKUM VEST GMBH Knappschaftskrankenhaus Recklinghausen

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 22, 2015
• First Posted: February 4, 2015
• Study Start: January 1, 2015
• Primary Completion: August 23, 2017
• Study Completion: August 23, 2017
• Last Updated: September 19, 2017

Record last verified: 2017-09

Data Sharing

• IPD Sharing: Will not share

Locations

DE (2)